Biotech Values

[acgood]

ONTY-

the very same interview broke another rule - he said that the delay in trial read out is probably a good thing - ""In some sense, the longer it takes the better it is" .... Plus the phase 3 trial is built off a subset analysis of a phase 2b that did not achieve it's primary endpoint

all in all surprised this one won a spot in even your charity portfolio

And a bonus quote re their PI3K program..."hopefully some competitors' will fail and the partners will come to us then"